IRMD
Iradimed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
RSI Overbought
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IRMD
Iradimed Corporation
A leader in the development of innovative magnetic resonance imaging compatible medical devices
Healthcare Equipment and Supplies
--
07/16/2014
NASDAQ Stock Exchange
160
12-31
Common stock
12705 Ingenuity Drive
Orlando
Florida 32826
--
Iradimed Corporation was incorporated in Oklahoma in July 1992 and re-incorporated in Delaware in April 2014. The company develops, manufactures, markets and distributes MRI-compatible medical devices and accessories, disposables and related services. The company is a leader in the development of innovative MRI-compatible medical devices. The company is the only known supplier of non-magnetic intravenous pump systems specifically designed for safe use during MRI examinations. The company pioneered an infusion delivery system that largely eliminates many of the dangers and problems that arise during MRI examinations.
Earnings Call
Q2/2025
Estimate EPS0.44
Actual EPS0.49
Estimate Revenue20.01M
Actual Revenue20.40M
Iradimed's Q2 2025 Earnings Call: Unpacking Key Contradictions in Pump Sales, Monitor Confidence, and Backlog Fulfillment
Aug 01,2025 01:14
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.46
Actual EPS0.47
Estimate Revenue20.50M
Actual Revenue21.20M
Iradimed's Q3 2025: Contradictions Emerge on Pump Sales Ramp, Gross Margin Outlook, Inventory Strategy, and Financial Forecasting
Nov 03,2025 03:58
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
IRMD has released its 2025 Q3 earnings. EPS was reported at 0.47, versus the expected 0.46, beating expectations. The chart below visualizes how IRMD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IRMD has released its 2025 Q3 earnings report, with revenue of 21.20M, reflecting a YoY change of 15.69%, and net profit of 5.58M, showing a YoY change of 10.44%. The Sankey diagram below clearly presents IRMD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
